Assessing TransMedics Gr: Insights From 6 Financial Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, six analysts have shared their insights on TransMedics Gr (NASDAQ:TMDX), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $160.17, with a high estimate of $200.00 and a low estimate of $120.00. Analysts have raised their price targets in response to the company's strong financial performance, including a 133.07% revenue growth rate and a net margin of 12.59%.
August 01, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransMedics Gr (NASDAQ:TMDX) has received a mix of bullish and somewhat bullish ratings from analysts, with an average 12-month price target of $160.17. The company's strong financial performance, including a 133.07% revenue growth rate and a net margin of 12.59%, has led to increased price targets.
The increase in average price target and the predominantly bullish ratings indicate positive sentiment among analysts. The company's strong financial metrics, such as high revenue growth and net margin, support this outlook, suggesting a likely short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100